Trials / Recruiting
RecruitingNCT06994195
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 384 (estimated)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-B01D1 | Administration by intravenous infusion for a cycle of 3 weeks. |
| DRUG | Liposomal doxorubicin, Paclitaxel or Topotecan | Administration by intravenous infusion for a cycle of 4 weeks. |
Timeline
- Start date
- 2025-08-04
- Primary completion
- 2027-06-01
- Completion
- 2027-12-01
- First posted
- 2025-05-29
- Last updated
- 2025-08-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06994195. Inclusion in this directory is not an endorsement.